Works matching IS 20457634 AND DT 2020 AND VI 9 AND IP 1

Results: 41
    1
    2
    3
    4

    Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 160, doi. 10.1002/cam4.2705
    By:
    • Chan, Kelvin K. W.;
    • Guo, Helen;
    • Cheng, Sierra;
    • Beca, Jaclyn M.;
    • Redmond‐Misner, Ruby;
    • Isaranuwatchai, Wanrudee;
    • Qiao, Lucy;
    • Earle, Craig;
    • Berry, Scott R.;
    • Biagi, James J.;
    • Welch, Stephen;
    • Meyers, Brandon M.;
    • Mittmann, Nicole;
    • Coburn, Natalie;
    • Arias, Jessica;
    • Schwartz, Deborah;
    • Dai, Wei F.;
    • Gavura, Scott;
    • McLeod, Robin;
    • Kennedy, Erin D.
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11

    Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 151, doi. 10.1002/cam4.2693
    By:
    • Wang, De‐shen;
    • Wang, Zhi‐qiang;
    • Chen, Gong;
    • Peng, Jie‐wen;
    • Wang, Wei;
    • Deng, Yan‐hong;
    • Wang, Feng‐hua;
    • Zhang, Jian‐wei;
    • Liang, Han‐lin;
    • Feng, Fen;
    • Xie, Chuan‐bo;
    • Ren, Chao;
    • Jin, Ying;
    • Shi, Si‐mei;
    • Fan, Wen‐hua;
    • Lu, Zhen‐hai;
    • Ding, Pei‐rong;
    • Wang, Feng;
    • Xu, Rui‐hua;
    • Li, Yu‐hong
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 116, doi. 10.1002/cam4.2674
    By:
    • Tran, Ben;
    • Ruiz‐Morales, Jose M.;
    • Gonzalez‐Billalabeitia, Enrique;
    • Patrikidou, Anna;
    • Amir, Eitan;
    • Seidel, Christoph;
    • Bokemeyer, Carsten;
    • Fankhauser, Christian;
    • Hermanns, Thomas;
    • Rumyantsev, Alexey;
    • Tryakin, Alexey;
    • Brito, Margarida;
    • Fléchon, Aude;
    • Kwan, Edmond Michael;
    • Cheng, Tina;
    • Castellano, Daniel;
    • Garcia del Muro, Xavier;
    • Hamid, Anis A.;
    • Ottaviano, Margaret;
    • Palmieri, Giovannella
    Publication type:
    Article
    24
    25
    26
    27

    A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 225, doi. 10.1002/cam4.2670
    By:
    • Boyle, Theresa A.;
    • Quinn, Gwendolyn P.;
    • Schabath, Matthew B.;
    • Muñoz‐Antonia, Teresita;
    • Saller, James J.;
    • Duarte, Luisa F.;
    • Hair, Laura S.;
    • Teer, Jamie K.;
    • Chiang, Derek Y.;
    • Leary, Rebecca;
    • Wong, Connie C.;
    • Savchenko, Alexander;
    • Singh, Angad P.;
    • Charette, LaSalette;
    • Mendell, Kate;
    • Gorgun, Gullu;
    • Antonia, Scott J.;
    • Chiappori, Alberto A.;
    • Creelan, Benjamin C.;
    • Gray, Jhanelle E.
    Publication type:
    Article
    28

    Reversibility of delirium in Ill‐hospitalized cancer patients: Does underlying etiology matter?

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 19, doi. 10.1002/cam4.2669
    By:
    • Matsuda, Yoshinobu;
    • Maeda, Isseki;
    • Morita, Tatsuya;
    • Yamauchi, Toshihiro;
    • Sakashita, Akihiro;
    • Watanabe, Hiroaki;
    • Kaneishi, Keisuke;
    • Amano, Koji;
    • Iwase, Satoru;
    • Ogawa, Asao;
    • Yoshiuchi, Kazuhiro;
    • Abo, Hirofumi;
    • Akechi, Tatsuo;
    • Akizuki, Nobuya;
    • Okuyama, Toru;
    • Fujisawa, Daisuke;
    • Hagiwara, Shingo;
    • Hirohashi, Takeshi;
    • Hisanaga, Takayuki;
    • Imai, Kengo
    Publication type:
    Article
    29
    30

    Connect MM Registry as a national reference for United States multiple myeloma patients.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 35, doi. 10.1002/cam4.2656
    By:
    • Ailawadhi, Sikander;
    • Jagannath, Sundar;
    • Narang, Mohit;
    • Rifkin, Robert M.;
    • Terebelo, Howard R.;
    • Toomey, Kathleen;
    • Durie, Brian G. M.;
    • Hardin, James W.;
    • Gasparetto, Cristina J.;
    • Wagner, Lynne;
    • Omel, James L.;
    • Kumar, Vivek;
    • Yue, Lihua;
    • Kitali, Amani;
    • Agarwal, Amit;
    • Abonour, Rafat
    Publication type:
    Article
    31
    32
    33
    34

    Modified EPOCH for high‐risk non‐Hodgkin lymphoma in sub‐Saharan Africa.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 77, doi. 10.1002/cam4.2631
    By:
    • Zuze, Takondwa;
    • Ellis, Grace K.;
    • Kasonkanji, Edwards;
    • Kaimila, Bongani;
    • Nyasosela, Richard;
    • Nyirenda, Ruth;
    • Tomoka, Tamiwe;
    • Mulenga, Maurice;
    • Chikasema, Maria;
    • Tewete, Blessings;
    • Mtangwanika, Asekanadziwa;
    • Chiyoyola, Sarah;
    • Chimzimu, Fred;
    • Kampani, Coxcilly;
    • Mhango, Wilberforce;
    • Nicholas, Simon;
    • Randall, Cara;
    • Montgomery, Nathan D.;
    • Fedoriw, George;
    • Westmoreland, Katherine D.
    Publication type:
    Article
    35

    Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese".

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 170, doi. 10.1002/cam4.2628
    By:
    • Di Renzo, Nicola;
    • Melillo, Lorella;
    • Porretto, Fernando;
    • Dargenio, Michela;
    • Pavone, Vincenzo;
    • Pastore, Domenico;
    • Mazza, Patrizio;
    • Mannina, Donato;
    • Merenda, Anxur;
    • Cascavilla, Nicola;
    • Greco, Giuseppina;
    • Matera, Rosella;
    • Bonizzoni, Erminio;
    • Celio, Luigi;
    • Musso, Maurizio
    Publication type:
    Article
    36
    37
    38

    Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 52, doi. 10.1002/cam4.2607
    By:
    • Mariotti, Jacopo;
    • Taurino, Daniela;
    • Marino, Fabrizio;
    • Bramanti, Stefania;
    • Sarina, Barbara;
    • Morabito, Lucio;
    • De Philippis, Chiara;
    • Di Vito, Clara;
    • Mavilio, Domenico;
    • Carlo‐Stella, Carmelo;
    • Della Porta, Matteo;
    • Santoro, Armando;
    • Castagna, Luca
    Publication type:
    Article
    39
    40
    41

    Issue Information.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 1, doi. 10.1002/cam4.2287
    Publication type:
    Article